Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 301-302 |
| Number of pages | 2 |
| Journal | JAMA Pediatrics |
| Volume | 171 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2017 |
Fingerprint
Cite this
}
Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply. / McMullan, Brendan J.; Bowen, Asha C.; Tong, Steven Y C.
In: JAMA Pediatrics, Vol. 171, No. 3, 03.2017, p. 301-302.Research output: Contribution to journal › Letter › Research › peer-review
TY - JOUR
T1 - Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply
AU - McMullan, Brendan J.
AU - Bowen, Asha C.
AU - Tong, Steven Y C
PY - 2017/3
Y1 - 2017/3
N2 - In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.
AB - In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.
UR - http://www.scopus.com/inward/record.url?scp=85015160536&partnerID=8YFLogxK
U2 - 10.1001/jamapediatrics.2016.4689
DO - 10.1001/jamapediatrics.2016.4689
M3 - Letter
VL - 171
SP - 301
EP - 302
JO - JAMA Pediatrics
JF - JAMA Pediatrics
SN - 1072-4710
IS - 3
ER -